Groupon Reports First Quarter 2025 ResultsMay 07, 2025 4:15 PM EDT | Source: GrouponGlobal Revenue down 5% and Billings up 1%North America Local Revenue down less than 1% and Local Billings up 11% International Local revenue declined 8%. Excluding Italy, International Local revenue grew 4%Chicago, Illinois--(Newsfile Corp. - May 7, 2025) - Groupon, Inc. (NASDAQ: GRPN) today announced its financial results for the first quarter ended March 31, 2025. The company filed its Form 10-Q with the Secu ...

Group 1 - LiqTech International, Inc. will report its first quarter 2025 financial results on May 14, 2025, before the market opens [1] - A conference call to review the results is scheduled for the same day at 9:00 a.m. Eastern time [1][2] - The conference call can be accessed via phone or a live webcast on the company's website [2] Group 2 - LiqTech International, Inc. specializes in high-tech filtration products and systems, particularly ceramic silicon carbide filtration technologies for gas and liquid purification [4] - The company's silicon carbide membranes are designed for challenging purification applications, including controlling diesel exhaust soot emissions [4] - LiqTech utilizes nanotechnology to develop a range of filtration products, offering unique turnkey solutions for water purification [4]

Core Insights - CrossAmerica Partners LP reported a net loss of $7.1 million for Q1 2025, an improvement from a net loss of $17.5 million in Q1 2024, indicating a challenging yet improving financial landscape for the company [4][5][6] - Adjusted EBITDA for Q1 2025 was $24.3 million, slightly up from $23.6 million in the same period last year, driven by increased gross profit in the retail segment [4][5][6] - The company continues to execute its asset rationalization strategy, enhancing its portfolio strength for future growth [3][4] Financial Performance - Net Income (Loss): Q1 2025 reported a loss of $7.1 million compared to a loss of $17.5 million in Q1 2024 [4][5] - Adjusted EBITDA: Increased to $24.3 million in Q1 2025 from $23.6 million in Q1 2024 [4][5] - Distributable Cash Flow: Decreased to $9.1 million in Q1 2025 from $11.7 million in Q1 2024 [4][5] - Distribution Coverage Ratio: Current quarter at 0.46x compared to 0.59x in Q1 2024; trailing twelve months at 1.04x compared to 1.37x [4][5] Retail Segment Highlights - Retail segment gross profit increased to $63.2 million in Q1 2025 from $54.4 million in Q1 2024, a 16% increase [7][8] - Motor fuel gallons distributed in the retail segment rose to 126.5 million from 121.7 million year-over-year [7][8] - Same-store merchandise sales excluding cigarettes decreased by 1% to $48.7 million in Q1 2025 [10] Wholesale Segment Highlights - Wholesale segment gross profit slightly decreased to $26.7 million in Q1 2025 from $27.0 million in Q1 2024 [12][13] - Motor fuel gallons distributed in the wholesale segment fell to 162.9 million from 184.0 million year-over-year [12][13] - Average wholesale gross profit per gallon increased to $0.097 from $0.079 [12][13] Asset Management and Divestment - CrossAmerica sold seven sites for $8.6 million in proceeds during Q1 2025, resulting in a net gain of $5.6 million [14] - The company is actively rationalizing its real estate assets to optimize its operational efficiency [14][6] Liquidity and Capital Resources - As of March 31, 2025, CrossAmerica had $778.0 million outstanding under its credit facility, with approximately $87.2 million available for future borrowings [15] - Leverage ratio was 4.27 times as of March 31, 2025, down from 4.36 times at the end of 2024 [15] Distribution Information - The Board declared a quarterly distribution of $0.5250 per limited partner unit for Q1 2025, to be paid on May 15, 2025 [16]

Q1 Net Revenue Increased 83% to $60.3 MillionSANTA CLARA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- SiTime Corporation, (Nasdaq: SITM), the Precision Timing company, today announced financial results for the first quarter ended March 31, 2025. Net revenue in the first quarter of 2025 was $60.3 million, as compared to $33.0 million in the year ago quarter. “Our Q1 revenue growth of 83% year-over-year highlights the strength of our business across our end markets,” said Rajesh Vashist, CEO and chairman of SiTi ...

Company Announcement - Oncocyte Corp. will report its first quarter 2025 financial results after the market closes on May 12, 2025 [1] - A live Zoom webinar will be held at 2:00 p.m. PT on the same day to discuss the financial results [1][2] Investor Information - The webinar will include a Q&A session and requires registration for access [2] - An archived replay of the webinar will be available on Oncocyte's investor relations website after the call concludes [2] Company Overview - Oncocyte is a diagnostics technology company focused on democratizing access to novel molecular diagnostic testing to enhance patient outcomes [3]

Core Viewpoint - Star Equity Holdings, Inc. will release its financial results for Q1 2025 on May 14, 2025, before market opens, followed by a conference call to discuss results and management's outlook [1]. Company Overview - Star Equity Holdings, Inc. is a diversified holding company with three business divisions: Building Solutions, Energy Services, and Investments [3]. Building Solutions Division - The Building Solutions division includes three businesses: modular building manufacturing, structural wall panel and wood foundation manufacturing (including building supply distribution), and glue-laminated timber (glulam) column, beam, and truss manufacturing [4]. Energy Services Division - The Energy Services division focuses on the rental, sale, and repair of downhole tools utilized in the oil and gas, geothermal, mining, and water-well industries [5]. Investments Division - The Investments division manages and finances the company's real estate assets and investment positions in both private and public companies [6].

First Quarter 2025 Highlights: PLAINVIEW, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its first quarter ended March 31, 2025. Results are reported in accordance with U.S. generally accepted accounting principles ("GAAP") and are also reported adjusting for certain items ("Non-GAAP"). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release. | U.S. Dollars in millions, except per share data ...

Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Supporting 711 global clinical trials as of March 31, 2025 Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial ...

Core Insights - RxSight, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $37.9 million, a 28% increase from $29.5 million in Q1 2024, driven by significant growth in Light Adjustable Lens (LAL) sales [4][9] - The company continues to emphasize the clinical value of its Light Adjustable Lens, which is gaining traction among cataract surgeons, and believes that customization and post-operative adjustability will be key trends in premium cataract surgery [3][9] Financial Performance - Total revenue for Q1 2025 was $37.9 million, up 28% from $29.5 million in Q1 2024, with LAL revenue increasing by 37% and Light Delivery Device (LDD) revenue rising by 8% [4][9] - Gross profit for Q1 2025 was $28.3 million, representing 74.8% of revenue, an increase from $20.7 million or 70.1% of revenue in Q1 2024, attributed to lower cost of sales and a favorable product mix [5][9] - Operating expenses for Q1 2025 totaled $39.0 million, a 24% increase from $31.4 million in Q1 2024, reflecting investments in LDD and R&D [6][9] - The net loss for Q1 2025 was $(8.2) million, or $(0.20) per share, an improvement from a net loss of $(9.1) million, or $(0.25) per share in Q1 2024 [7][9] Guidance and Market Position - The company reiterated its full-year 2025 revenue guidance of $160.0 million to $175.0 million, indicating growth of 14% to 25% compared to 2024 [10] - Gross margin is expected to be in the range of 71% to 73%, while operating expenses are projected to be between $150.0 million and $160.0 million, reflecting a 10% to 18% increase compared to 2024 [10][11] - RxSight sold 27,579 LALs in Q1 2025, a 36% increase in procedure volume compared to the same period in 2024, and expanded its installed base of LDDs to 1,044, a 43% increase year-over-year [9][10]

"Our MCM business in the U.S. continues to deliver very strong results. Empowered by the ongoing favorable supply environment, MCM portfolio purchases in the first quarter were a record $316 million, up 34% compared to the year ago quarter, at very attractive returns. MCM also delivered record collections of $454 million in the first quarter, up 23% compared to Q1 a year ago, driven by superior execution." "Our Cabot business in Europe delivered a solid first quarter. Portfolio purchases of $51 million were ...